TrialClinical and translational science2022

Safety, pharmacokinetics and target engagement of novel RIPK1 inhibitor SAR443060 (DNL747) for neurodegenerative disorders: Randomized, placebo-controlled, double-blind phase I/Ib studies in healthy subjects and patients.

Maurits F J M Vissers et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.